PROCEPT BioRobotics Q2 2024 GAAP EPS $(0.50) Beats $(0.52) Estimate, Sales $53.353M Beat $50.164M Estimate
Portfolio Pulse from Benzinga Newsdesk
PROCEPT BioRobotics (NASDAQ:PRCT) reported Q2 2024 GAAP EPS of $(0.50), beating the $(0.52) estimate. Sales were $53.353M, surpassing the $50.164M estimate and marking a 61.17% increase from the same period last year.
August 01, 2024 | 8:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PROCEPT BioRobotics reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.50) beating the $(0.52) estimate and sales of $53.353M surpassing the $50.164M estimate. Sales increased by 61.17% YoY.
The better-than-expected earnings and significant year-over-year sales growth are likely to positively impact PRCT's stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100